BioSpace News Archive

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter—basically a rejection—to Austin, Texas-based Pain Therapeutics for Remoxy ER for pain.

Regeneron Pharmaceuticals and bluebird bio are teaming up. The companies will combine their expertise in the battle against cancer by leveraging Regeneron’s VelociSuite platform with bluebird’s cell therapy technologies to develop new cell therapies for patients.

This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or biotech industries.

Mark Emalfarb, founder, chairman and chief executive officer of Jupiter, Florida-based Dyadic International, believes he knows how to revolutionize biopharma manufacturing. Emalfarb took time out to talk to BioSpace about his company and its C1 technology platform.

Reuters recently issued a special report focusing on National Securities Corp., alleging conflicts of interest when the company’s analysts recommend certain biotech companies.

Yancopoulos, Regeneron’s founder and chief scientific officer, and Schleifer, chief executive officer, argue in the article that while drug affordability is important, the single-minded argument detracts from “the overwhelming health care crisis facing our society” and creates a negative image of an industry that provides substantial benefit to society.

Biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those adjustments.

Ovid Therapeutics is shouting good news from the rooftops regarding its mid-stage Angelman Syndrome study, but investors are not convinced.

Scientists with Framingham, Massachusetts-based Alzheon identified a substance in the human brain that inhibits the formation of beta-amyloid, the primary driver of Alzheimer’s disease. The substance is 3-sulfopropanoic acid (3-SPA).

At some point in time, most of us have been asked to do more with less on the job. You can take control of your career! Here are 5 tips to avoid employee burnout.